Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHAP Medicare Part B Prior Auth & Step Therapy | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealth Alliance Plan (HAP)Policy N/A

    HAP Medicare Part B Prior Authorization and Step Therapy Criteria

    Customize your policy alerts

    Sign up for all Health Alliance Plan (HAP) policy alerts

    Know when Health Alliance Plan (HAP) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and step therapy requirements, documentation expectations, and coverage determination approach for outpatient drugs and biologics billed under HAP Medicare Part B for providers submitting Part B drug requests.

    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyHAP Medicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting medical records (diagnosis, prior therapy trials, and required diagnostic documentation) before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Jan 2026document effective / publication month
    1 yeartypical max coverage duration
    >=18age minimum (some indications)
    PND ≤ IIIbbaseline neuropathy requirement
    medical recordsdocumentation required

    Coverage Criteria

    General Part B drug coverage criteria

    Covered when requirements below are met and consistent with applicable Medicare coverage guidance:

    General coverage logic: All applicable Medicare NCDs/LCDs/LCAs must be satisfied; when such guidance is absent HAP may require the drug be used for a medically accepted indication supported by CMS‑approved compendia or peer‑reviewed literature; prior authorization submissions must include required medical information and supporting medical records (indication, prior therapy trials, prescriber specialty when specified).

    Applies generally; specific drugs have additional criteria such as prescriber specialty, genetic testing, prior biologic trials, step therapy, or exclusions.

    hATTR FAP coverage criteria (initial)

    Covered when ALL of the following are met for transthyretin-related familial amyloid polyneuropathy (hATTR FAP):

    hATTR FAP initial criteria: 1) Medical records supporting the request are provided; AND 2) Documentation of a pathogenic transthyretin (TTR) gene mutation (e.g., V30M); AND 3) Baseline polyneuropathy disability (PND) score ≤ IIIb and/or baseline FAP Stage 1 or 2; AND 4) Documentation of clinical signs and symptoms of hATTR FAP (e.g., motor disability, peripheral or autonomic neuropathy).
    Policy Summary
    PayerHealth Alliance Plan (HAP)
    PolicyHAP Medicare Part B Prior Authorization and Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting medical records (diagnosis, prior therapy trials, and required diagnostic documentation) before requesting coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Actions and Documentation RequirementsInitial Therapy CriteriaReauthorization / Continuation CriteriaStep Therapy RulesQuantity Limits and AdministrationSite of CareBiosimilar and Alternative PreferenceDefinitions
    PND ≤ IIIb or FAP Stage 1 or 2

    From Required Medical Information group for Amvuttra/vutrisiran entries (effective 1/1/2026).

    Transthyretin amyloid cardiomyopathy coverage criteria (initial)

    Covered when ALL of the following are met for transthyretin amyloid cardiomyopathy (wild-type or hereditary):

    Cardiomyopathy coverage criteria: 1) Confirmation of transthyretin amyloid cardiomyopathy diagnosis with appropriate diagnostic testing; AND 2) Patient meets applicable age requirement (see age threshold).

    Specific diagnostic tests not listed in these chunks; documentation required.

    Transthyretin-related familial amyloid polyneuropathy (hATTR)

    Covered when ALL of the following are met:

    hATTR initial coverage: 1) Medical records supporting the request are provided; AND 2) Documentation of a transthyretin (TTR) mutation (e.g., V30M); AND 3) Baseline PND score ≤ IIIb and/or baseline FAP Stage 1 or 2; AND 4) Documentation of clinical signs and symptoms (e.g., motor disability, peripheral/autonomic neuropathy).PND ≤ IIIb or FAP Stage 1–2

    Applies to hereditary transthyretin-related familial amyloid polyneuropathy.

    Transthyretin amyloid cardiomyopathy (wild-type or hereditary)

    Covered when ALL of the following are met:

    Cardiomyopathy initial coverage: 1) Confirmation of diagnosis with appropriate testing for transthyretin amyloid cardiomyopathy (wild-type or hereditary); AND 2) Patient is at least 18 years of age.age ≥ 18

    Age requirement stated for cardiomyopathy indication.

    General coverage criteria (partial)

    Covered when the following are met (as referenced in document chunks):

    Age requirement: Patient must be at least 18 years of age.>=18 years

    Stated repeatedly for relevant indications (e.g., cardiomyopathy).

    Diagnosis confirmation: For transthyretin amyloid cardiomyopathy confirmation of diagnosis with appropriate testing is required.N/A

    Document references confirmation but does not list specific tests in these chunks

    Prescriber restrictions: No prescriber restrictions are indicated (Prescriber Restrictions: N/A) unless specified for a particular drug elsewhere in the policy.N/A

    Explicitly stated as N/A in multiple chunks

    Epysqli (eculizumab-aagh) — NMOSD

    Selected detailed criteria for Epysqli (eculizumab-aagh) from this section

    NMOSD coverage criteria: For neuromyelitis optica spectrum disorder (NMOSD): 1) Patient is anti-aquaporin-4 (AQP4) antibody positive; AND 2) Patient exhibits an NMOSD core clinical characteristic (optic neuritis, acute myelitis, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy/diencephalic syndrome, or symptomatic cerebral syndrome with NMOSD-typical lesions); AND 3) Patient has tried and failed Uplizna (inadequate response or intolerance); AND 4) Patient has tried and failed Enspryng; AND 5) EDSS score ≤ 7; AND 6) Epysqli is not used in combination with Ultomiris, Uplizna, Enspryng, or other NMOSD medications; AND 7) For reauthorization provide documentation of decreased relapse rate.EDSS ≤7

    Prescriber: neurologist or in consultation with neurologist recommended in related chunks.

    Epysqli (eculizumab-aagh) — MG, aHUS, PNH

    Epysqli criteria for other indications

    Myasthenia gravis coverage criteria: 1) Baseline MG-ADL score ≥ 6; AND 2) Confirmed diagnosis of generalized myasthenia gravis that is anti‑AChR antibody positive; AND 3) Trial of one non-steroid generic immunosuppressant (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate, tacrolimus) for ≥6 months with inadequate response or intolerance; AND 4) Epysqli must not be used in combination with IVIG, Vyvgart, Ultomiris, Rystiggo, or Zilbrysq; AND 5) For reauthorization document improvement in MG-ADL from baseline.MG-ADL ≥6

    Initial and reauthorization requirements.

    aHUS coverage criteria: 1) Shiga toxin–related HUS and TTP must be ruled out; AND 2) For reauthorization, document decreased signs of thrombotic microangiopathy (e.g., normalization of platelets and LDH; reduction in serum creatinine).

    aHUS reauthorization guidance.

    PNH coverage criteria: 1) Diagnosis confirmed by flow cytometry; AND 2) Presence of hemolysis‑associated symptoms (thrombosis, organ dysfunction, pain); AND 3) Not used in combination with other complement drug therapy (Fabhalta, Ultomiris, Empaveli); AND 4) For reauthorization document improvement in PNH‑related symptoms and hematologic markers (sustained Hb increase, reduced transfusions).

    PNH initial and reauthorization criteria.

    Evenity (romosozumab-aqqg)

    Romosozumab (Evenity) criteria

    Evenity coverage criteria: 1) Prescribed by an endocrinologist; AND 2) Patient has tried and failed Prolia (failure defined as intolerance, decreased BMD versus prior DEXA, new fracture on therapy, or contraindication); AND 3) Cumulative use >12 months is not covered (coverage limited to 12 months per lifetime).12 months lifetime limit

    Specialist prescriber required; reauthorization constrained by lifetime duration.

    Trastuzumab (Herceptin and biosimilars) - Initial coverage

    Covered when ALL of the following are met

    Trastuzumab PA/step: 1) Patient requires trastuzumab for a medically accepted indication; AND 2) Patient has trialed the biosimilars Trazimera AND Kanjinti prior to other trastuzumab formulations; AND 3) Dose and duration consistent with FDA labeling or accepted standards of medical practice; AND 4) Coverage duration typically up to 1 year.

    Hympavzi (marstacimab) - Initial coverage

    Covered when ALL of the following are met

    Hympavzi PA criteria: 1) Member has documented hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors; AND 2) Prescription written by a hematologist; AND 3) Medical records document prior prophylaxis trials (hemophilia A: two prophylaxis drugs including Hemlibra; hemophilia B: two prophylaxis drugs such as Alprolix, BeneFIX, or Idelvion); AND 4) Initial dosing: loading 300 mg (two 150 mg injections) subcutaneously, then maintenance 150 mg weekly beginning one week after loading; AND 5) Dose escalation to 300 mg weekly requires documentation of medical necessity (e.g., increased spontaneous bleeding); AND 6) Not to be used in combination with other prophylaxis drugs for hemophilia.

    iDose TR (travoprost intracameral implant) - Initial coverage

    Covered when ALL of the following are met

    iDose TR PA criteria: 1) Medical records supporting the request are provided; AND 2) Patient has diagnosis of open‑angle glaucoma or ocular hypertension; AND 3) Patient meets one of the following pathways: (a) tried and failed one generic topical prostaglandin eye drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR (b) is unable to use Durysta and has tried and failed two generic topical prostaglandin eye drops. 'Failed' is defined as inadequate response, intolerance, or demonstrated compliance issues.

    Initial Therapy

    Covered when ALL of the following are met

    Overall requirements: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) Patient meets one of the prior therapy pathways (a OR b).

    See pathway options below.

    Pathway a or b: a) Patient has tried and failed one generic prostaglandin topical drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR b) Patient is unable to use Durysta and has tried and failed two generic topical prostaglandin drops.

    'Failed' defined as inadequate response, intolerance, or documented compliance issues.

    Initial therapy / Prior authorization criteria

    Covered when ALL of the following are met

    Primary criteria: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) One of the following must be met (Path A or Path B).

    Documentation of prior trials required.

    Step therapy options: a) Tried and failed one generic prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) AND Durysta; OR b) Unable to use Durysta and tried and failed two generic topical prostaglandin eye drops.

    'Failed' defined as inadequate response, intolerance, or compliance issues.

    Initial Therapy

    Covered when ALL of the following are met

    Diagnosis: Patient has open‑angle glaucoma or ocular hypertension.
    Documentation: Medical records supporting the request must be provided.

    Prior medication trials (two alternative paths)

    • Path A: Tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, or travoprost) AND Durysta.

      Failed defined as inadequate response, intolerance, or compliance issues.

    • Path B: Unable to use Durysta AND tried and failed two generic topical prostaglandin eye drops.

      Failed defined as inadequate response, intolerance, or compliance issues.

    Initial authorization criteria

    Covered when ALL of the following are met

    Main criteria: 1) Medical records supporting the request are provided; AND 2) Patient has open‑angle glaucoma or ocular hypertension; AND 3) Patient meets one of the following: (a) tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin eye drops.

    'Failed' = inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops.

    Initial coverage criteria

    Covered when ALL of the following are met

    Primary indication: Patient has open‑angle glaucoma or ocular hypertension.
    Prior trial pathways: Patient meets one of the following: (a) tried and failed one generic prostaglandin drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin drops.

    'Failed' defined as inadequate response, intolerance, or compliance issues.

    Initial therapy / Coverage criteria

    Covered when ALL of the following are met

    iDose TR coverage criteria: 1) Patient has open‑angle glaucoma or ocular hypertension; AND 2) Patient meets one of the following: (a) tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin eye drops. 'Failed' is defined as inadequate response, intolerance, or documented compliance issues.

    Coverage is limited to one‑time administration per FDA labeling or accepted standards of practice.

    Initial coverage criteria

    Covered when ALL of the following are met:

    Primary requirements: 1) Diagnosis of open‑angle glaucoma or ocular hypertension; AND 2) One of the following: (a) tried and failed one generic prostaglandin eye drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin eye drops.

    'Failed' means inadequate response, intolerance, or demonstrated compliance issues. Coverage generally limited to one‑time administration.

    Initial coverage criteria

    Covered when ALL of the following are met

    Primary indication: Patient has open‑angle glaucoma or ocular hypertension.
    Prior therapy requirement: (a) Tried and failed one generic prostaglandin drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR (b) Unable to use Durysta and tried and failed two generic topical prostaglandin drops.

    'Failed' = inadequate response, intolerance, or demonstrated compliance issues.

    Administration limit: One‑time administration as indicated per FDA‑approved labeling or within accepted standards of medical practice.one-time

    Quantity limit applied to iDose TR in multiple chunks.

    Initial coverage criteria

    Covered when ALL of the following are met:

    Primary indication: Patient has open‑angle glaucoma or ocular hypertension.
    Medication trials: One of the following must be met: (a) patient tried and failed one generic prostaglandin drop (latanoprost, bimatoprost, or travoprost) AND Durysta; OR (b) patient is unable to use Durysta and has tried and failed two generic topical prostaglandin drops.

    Failed defined as inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops.

    Some drugs in this policy include explicit exclusions that prohibit combination use with other specified agents or require absence of certain clinical states. For example, trasthyretin-related familial amyloid polyneuropathy entries note that the agent must not be used in combination with TTR stabilizers (e.g., tafamidis) or TTR-lowering agents (e.g., Onpattro), and patients must not have had a liver transplant when these exclusions apply. Providers should confirm per‑drug exclusion statements when submitting prior authorization requests.

    No explicit exclusions are stated in the cited sections for the referenced agents. Clinical reviewers should rely on the detailed, per‑drug criteria elsewhere in the document and on applicable Medicare NCDs/LCDs/LCAs for any exclusionary guidance.

    The provided excerpts do not list explicit exclusion conditions. Where exclusions apply they are documented in the specific drug entries; absent such language, standard coverage criteria and documentation requirements apply.

    Certain products carry specific noncoverage exclusions. Evenity (romosozumab) has a lifetime cumulative use limit: cumulative use beyond 12 months is not covered. Additionally, Evkeeza (evinacumab) entries state it must not be used in combination with a PCSK9 inhibitor (e.g., Repatha), Nexletol, or Nexlizet. These combination exclusions and lifetime limits should be confirmed on the drug‑specific criteria when requesting authorization.

    For hemophilia prophylaxis, Hympavzi (marstacimab) must not be used in combination with other drugs indicated for prophylaxis for hemophilia A or B. Prior authorization requires documentation of diagnosis without inhibitors and prior prophylaxis trials; combination use with other prophylactic agents is an exclusion that will risk denial if not adhered to.

    No age restrictions are specified in these excerpts except where explicitly noted for particular indications. Where age limits are required by an indication (for example, transthyretin amyloid cardiomyopathy entries require the patient to be at least 18 years of age), that requirement is indicated in the relevant drug criteria.

    This excerpt does not list any explicit exclusions. Absent an exclusion statement in the drug‑specific section, reviewers should apply the stated coverage criteria and documentation rules.

    No age or prescriber restrictions are specified in this segment; the excerpts list Age Restrictions: N/A and Prescriber: N/A. Confirm per‑drug requirements elsewhere in the policy when prescriber specialty is necessary.

    The cited sections indicate Age Restrictions: N/A and Prescriber Restrictions: N/A for the items shown. If a prescriber requirement exists (e.g., some products require a hematologist or endocrinologist), it will be stated in the specific drug entry and must be met for approval.

    These excerpts do not include explicit age or prescriber restrictions and list both fields as N/A. Where coverage requires a specialist prescriber or age limit that requirement appears in the individual drug criteria (for example, Evenity requires an endocrinologist).

    No specific clinical exclusions are listed here beyond the effect of not meeting required prior trial or diagnostic criteria. For example, denial risks are tied to failure to meet documented prior‑therapy requirements or to missing diagnostic evidence (such as TTR mutation, baseline PND/FAP staging) rather than additional explicit exclusions in these excerpts.

    No age or prescriber restrictions are specified in this excerpt; the policy sections cite Age Restrictions: N/A and Prescriber Restrictions: N/A. Confirm individual product pages for any specialty prescriber requirements.

    This section does not state explicit exclusions. Coverage is dictated by meeting the documented clinical criteria (diagnosis, prior medication trials, and required supporting medical records); absence of those will lead to noncoverage.

    Requests that lack the required documentation, are inconsistent with applicable Medicare NCDs/LCDs/LCAs, or are not supported by medically accepted compendia or peer‑reviewed evidence may be determined not reasonable and necessary and therefore not covered. Providers should include medical records, prior therapy trials, and supporting rationale when requesting exceptions.

    No explicit 'not medically necessary' determinations are stated in these chunks. However, failure to meet the specified coverage criteria or to provide required documentation would imply the request is not reasonable and necessary and could be denied.

    The cited excerpts do not list explicit 'not medically necessary' conditions. Reviewers should apply the stated clinical criteria and documentation requirements; absence of required elements may lead to a determination of non‑medical necessity.

    The policy explicitly states that cumulative use of Evenity beyond 12 months is not covered; such use is considered not medically necessary. That lifetime limit is a clear basis for denial if exceeded.

    For intracameral travoprost (iDose TR), the requested eye must not have received prior treatment with IDOSE TR as an exclusion in multiple entries. In addition, failure to provide the required prior topical trial documentation or other required records may render the request not medically necessary and result in denial.

    This segment does not list additional specific 'not medically necessary' conditions beyond those tied to failure to meet the clinical criteria or missing documentation. Absent required documentation or prior‑therapy trials, coverage would generally not be approved under the stated criteria.

    Coding and Clinical Thresholds

    Procedure/J-codes referencedHCPCS
    J9035Chemotherapy
    J9044Bortezomib injection
    J9046Bortezomib injection
    J9048Bortezomib injection
    J9054Bortezomib injection
    J9041Alternate bortezomib J-code (must try two listed first)
    J9049Alternate bortezomib J-code
    J9051Alternate bortezomib J-code
    Trastuzumab products and biosimilarsmixed
    trastuzumab productsHerceptin, Herceptin Hylecta (trastuzumab/hyaluronidase-oysk), Hercessi (trastuzumab-strf), Herzuma (trastuzumab-pkrb), Trazimera, Kanjinti
    Hemophilia prophylaxismixed
    Hympavzimarstacimab hncq injection
    Ophthalmic productsmixed
    iDose TRtravoprost intracameral implant
    Durystabimatoprost intracameral implant or intracameral sustained-release (named Durysta in text)
    topical prostaglandin dropslatanoprost, bimatoprost, travoprost
    Baseline polyneuropathy disability (PND) score — ≤ IIIb
    Baseline PND requirementBaseline polyneuropathy disability (PND) score ≤ IIIb
    ContextRequired for hATTR FAP initial authorization (part of Amvuttra/vutrisiran criteria)
    DocumentationMedical records must document baseline PND score as part of required supporting information
    Baseline FAP Stage — Stage 1 or 2
    Acceptable baseline FAP stagesBaseline FAP Stage 1 or 2
    ContextRequired for hATTR FAP initial authorization (Amvuttra/vutrisiran criteria)
    DocumentationMedical records must include baseline FAP staging as part of required supporting information
    Baseline PND / FAP — PND score ≤ IIIb and/or baseline FAP Stage 1 or 2
    Combined eligibility thresholdPND score ≤ IIIb and/or baseline FAP Stage 1 or 2
    IndicationApplies to transthyretin-related familial amyloid polyneuropathy (hATTR FAP) coverage criteria
    Documentation requirementMedical records must show baseline PND and/or FAP stage to support authorization
    Age (cardiomyopathy) — must be at least 18 years of age
    Minimum agePatient must be at least 18 years of age
    ApplicabilityRequired for transthyretin amyloid cardiomyopathy (wild-type or hereditary) coverage
    DocumentationAge must be documented in submitted medical records for PA
    EDSS score — ≤7
    EDSS thresholdExpanded Disability Status Scale (EDSS) score ≤ 7
    Use caseRequired for Epysqli (eculizumab-aagh) NMOSD coverage criteria
    DocumentationBaseline EDSS score must be provided in medical records for authorization

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required for certain Part B drugs

    Certain Medicare Part B drugs listed in this document require prior authorization (PA). PA must be obtained before HAP may approve coverage and to determine whether the drug is covered under the medical (Part B) or pharmacy (Part D) benefit.

    Prior Authorization

    PA submission details and required fields

    Submit prior authorization requests via the HAP Provider Portal and include required medical information: indication, prior therapy trials (when applicable), prescriber specialty when required, and supporting medical records; requests will be reviewed per FDA labeling or accepted standards of medical practice.

    • Use the HAP Provider Portal on www.hap.org to submit PA requests.
    • Include indication, documented prior trials, prescriber specialty if specified, and supporting records.
    Documentation Required

    Medical records and diagnostic documentation required for PA

    PA requests must include specified supporting medical records and diagnostic documentation as described in the documentation requirements for each agent (e.g., genetic test results, baseline scores, prior therapy records).

    • Provide medical records that document prior therapies and responses to treatment.
    • Include diagnostic documentation specified for the indication (see per‑drug documentation requirements).
    Documentation Required

    PA documentation for transthyretin-related indications

    PA determinations require submission of supporting medical records and, for inherited transthyretin neuropathy, documentation such as a pathogenic TTR mutation (e.g., V30M), baseline PND score ≤ IIIb and/or baseline FAP Stage 1 or 2, and clinical signs/symptoms.

    • TTR mutation documentation (example: V30M).
    • Baseline PND score ≤ IIIb and/or baseline FAP Stage 1 or 2.
    • Clinical signs/symptoms (motor disability, peripheral/autonomic neuropathy).
    Prior Authorization

    PA applies to Amvuttra (vutrisiran) with diagnostic and age requirements

    Amvuttra (vutrisiran) injection requires prior authorization; for transthyretin amyloid cardiomyopathy confirm diagnosis with appropriate testing and for all indications ensure age and diagnostic requirements are met as specified.

    • Amvuttra effective 1/1/2026 — documentation required per indication.
    • For cardiomyopathy, provide confirmation of diagnosis with appropriate testing; age ≥18 where noted.
    Prior Authorization

    PA and typical coverage duration

    Prior authorization is required for many specialty drugs in this document; coverage duration is generally up to 1 year and dosing will be approved according to FDA labeling or accepted standards of medical practice.

    • Typical coverage duration referenced: up to 1 year.
    • Dose approvals follow FDA‑approved labeling or accepted standards of medical practice.
    Step Therapy

    Trastuzumab PA plus biosimilar-first step

    Trastuzumab products (including Herceptin, Herceptin Hylecta, Hercessi, Herzuma, etc.) require prior authorization and step therapy: patient must first try the biosimilars Trazimera AND Kanjinti before other trastuzumab formulations will be approved.

    • Coverage duration generally up to 1 year; dose per FDA labeling.
    • Must trial Trazimera AND Kanjinti prior to other trastuzumab products.
    Prior Authorization

    Hympavzi PA: diagnosis, prescriber, prior trials, dosing

    Hympavzi (marstacimab) requires prior authorization with documentation of hemophilia A or B without inhibitors, prescription by a hematologist, documentation of prior prophylaxis trials (for hemophilia A: two drugs including Hemlibra; for B: two prophylaxis drugs such as Alprolix, BeneFIX, or Idelvion), and adherence to the specified loading and maintenance dosing.

    • Prescription must be written by a hematologist.
    • Document absence of factor VIII or IX inhibitors.
    • Document prior prophylaxis trials (Hemlibra required among trials for hemophilia A).
    • Initial loading and maintenance dosing per criteria (300 mg loading; 150 mg weekly maintenance).
    Prior Authorization

    iDose TR PA: diagnosis plus step‑therapy documentation

    iDose TR (travoprost intracameral implant) requires prior authorization with medical records showing a diagnosis of open‑angle glaucoma or ocular hypertension and meeting step‑therapy trial requirements (either one generic prostaglandin trial plus Durysta, or inability to use Durysta plus two failed generic prostaglandin trials).

    • Provide medical records documenting diagnosis of open‑angle glaucoma or ocular hypertension.
    • Pathway A: failed one generic prostaglandin (e.g., latanoprost, bimatoprost, travoprost) AND Durysta.
    • Pathway B: unable to use Durysta AND tried and failed two generic topical prostaglandin drops.
    • 'Failed' = inadequate response, intolerance, or documented compliance issues.
    Documentation Required

    PA documentation required for iDose TR

    Prior authorization for iDose TR must include medical records demonstrating diagnosis of open‑angle glaucoma or ocular hypertension and documentation of required prior therapy trials per the two alternative pathways; failure must be documented as inadequate response, intolerance, or compliance issues.

    • Medical records showing which agents were tried and the clinical response or intolerance.
    • If Durysta was used, document Durysta trial and failure; if not usable, document reason unable to use Durysta and two failed generic prostaglandin trials.
    Prior Authorization

    PA requirement and step‑therapy precondition for iDose TR

    Prior authorization is required for iDose TR; patient must have open‑angle glaucoma or ocular hypertension and meet step‑therapy trial requirements (one generic prostaglandin + Durysta OR inability to use Durysta plus two generics) before approval.

    • Age and prescriber restrictions: Age N/A; Prescriber N/A unless specified elsewhere.
    • Ensure documentation of failed trials per definition before PA approval.
    Prior Authorization

    PA contingent on meeting iDose TR clinical and documentation criteria

    Prior authorization is required and approval for iDose TR is contingent on meeting the specified prior therapy requirements and providing medical records that document diagnosis and prior medication trials.

    • Document diagnosis of open‑angle glaucoma or ocular hypertension.
    • Provide records that demonstrate prior topical prostaglandin and Durysta trials (or inability to use Durysta).
    Prior Authorization

    PA required; one‑time administration and criteria for iDose TR

    Prior authorization is required for iDose TR when all criteria are met; the implant is a one‑time administration and PA should document diagnosis and prior therapy trials per the policy pathways.

    • One‑time administration only; coverage limited to a single administration as indicated per FDA labeling.
    • PA must show which pathway (A or B) the patient meets and supporting records.
    Prior Authorization

    PA required — iDose TR indication and prior trial requirement

    Prior authorization is required when using iDose TR; the patient must have open‑angle glaucoma or ocular hypertension and must meet required prior trial pathways (see coverage criteria for Path A or B).

    • 'Failed' trials must be clearly documented (inadequate response, intolerance, or compliance issues).
    Prior Authorization

    PA/Step therapy required for iDose TR — approval contingent on trials

    PA and step therapy are required for iDose TR; approval is contingent on documentation that the patient has open‑angle glaucoma or ocular hypertension and met the topical prostaglandin/Durysta trial requirements.

    • Provide evidence of prior topical prostaglandin failures and Durysta trial or documented inability to use Durysta.
    Prior Authorization

    PA required — documentation of prior topical trials and one‑time administration

    Prior authorization is required and coverage is contingent on meeting clinical criteria including diagnosis plus required prior topical prostaglandin trial(s) and Durysta trial where specified.

    • Document specific agents tried and outcomes (response, intolerance, compliance).
    • Coverage duration and administration limits (one‑time) apply per FDA labeling.
    Billing Rule

    PA required — iDose TR one‑time administration limit

    Prior authorization is required for one‑time administration of the iDose TR intracameral implant; coverage is limited to a single administration as indicated per FDA labeling or accepted standards of medical practice.

    • PA must document diagnosis and prior therapy pathway met.
    • Limit: one‑time administration per course.
    Step Therapy

    PA/Step therapy pathways required for iDose TR

    Prior authorization/step therapy for iDose TR must demonstrate: (1) diagnosis of open‑angle glaucoma or ocular hypertension; AND (2) either failed one generic topical prostaglandin plus Durysta, or inability to use Durysta with failure of two generic topical prostaglandin drops.

    • Path A: one generic topical prostaglandin (latanoprost, bimatoprost, travoprost) + Durysta — both tried and failed.
    • Path B: unable to use Durysta and tried and failed two generic topical prostaglandin drops.
    • Failure = inadequate response, intolerance, or demonstrated compliance issues.
    Step Therapy

    General step therapy requirement and failure definition

    Step therapy requires documented trial and failure of preferred or more cost‑effective drugs before progressing to non‑preferred Part B agents; failure must be shown as inadequate response or intolerance in the medical record.

    • Failure must be indicated by the provider or documented in medical records.
    • Applies to MAPD members not currently receiving the Part B drug.
    Note

    No other step therapy sequencing specified

    No additional sequencing beyond the specified per‑drug step requirements is defined in other sections of the document.

    Step Therapy

    Step therapy: biosimilar and alternative trial requirements

    Step therapy rules vary by drug; where specified, HAP requires trials of preferred biosimilars or alternatives (examples include biosimilar‑first requirements for trastuzumab and trials of Avastin or specific biosimilars for ophthalmic/chemotherapy agents).

    • Examples: must try Mvasi AND Zirabev prior to some bevacizumab product approvals; Trazimera AND Kanjinti required before other trastuzumab formulations.
    Step Therapy

    Trastuzumab biosimilar‑first step requirement

    For trastuzumab products the policy requires trial of the biosimilars Trazimera AND Kanjinti before other trastuzumab formulations will be approved.

    • Document prior trials of Trazimera and Kanjinti in the medical record before submitting PA for other trastuzumab products.
    Step Therapy

    Hympavzi step therapy: prior prophylaxis trials required

    For Hympavzi, step therapy requires documented prior trials of two prophylactic agents (for hemophilia A one trial must include Hemlibra; for hemophilia B examples include Alprolix, BeneFIX, or Idelvion) prior to approval.

    • Document prior prophylaxis agents tried and outcomes.
    • Ensure prescription is by a hematologist and show absence of inhibitors.
    Step Therapy

    iDose TR step therapy pathways and failure definition

    iDose TR step therapy requires either: (a) trial and failure of one generic topical prostaglandin eye drop (e.g., latanoprost, bimatoprost, travoprost) plus Durysta, or (b) inability to use Durysta and failure of two generic topical prostaglandin eye drops; 'failed' is defined as inadequate response, intolerance, or compliance issues.

    • Specify agents tried and clinical response in submitted records.
    • If patient cannot use Durysta, provide reason and document two failed generic prostaglandin trials.
    Documentation Required

    Required supporting documentation for PA/step requests

    Medical records supporting PA and step‑therapy requests must be provided, including documentation of prior therapies and responses to treatment; for off‑label or exception requests include peer‑reviewed literature as supporting evidence.

    • Include medical records showing prior therapies, dates, and clinical outcomes.
    • Attach literature or rationale when requesting exceptions for dosing, route, or off‑label use.
    Documentation Required

    Required supporting documentation for transthyretin indications

    Submit medical records supporting transthyretin‑related requests that include documentation of a pathogenic TTR mutation (example V30M), baseline PND score ≤ IIIb and/or FAP Stage 1 or 2, and clinical signs/symptoms; for cardiomyopathy provide confirmation testing.

    • TTR mutation documentation (e.g., V30M).
    • Baseline PND ≤ IIIb and/or baseline FAP Stage 1 or 2.
    • Clinical signs/symptoms (motor disability, peripheral/autonomic neuropathy).
    • Confirmation testing for transthyretin amyloid cardiomyopathy.
    Documentation Required

    Hemophilia prophylaxis documentation and exclusion

    Medical records supporting requests must be provided for hemophilia prophylaxis products and must document diagnosis of hemophilia A or B without inhibitors; combination use with other prophylaxis drugs is not permitted.

    • Document absence of factor VIII or IX inhibitors.
    • Do not submit requests showing concurrent use with other prophylactic hemophilia agents.
    Documentation Required

    Required documentation for ophthalmic implant (iDose TR) requests

    Medical records supporting ophthalmic implant requests must document diagnosis of open‑angle glaucoma or ocular hypertension and prior topical prostaglandin and Durysta trials (or inability to use Durysta) including which agents were tried and the reason they failed.

    • List agents tried (e.g., latanoprost, bimatoprost, travoprost) and dates.
    • Document failure reason: inadequate response, intolerance, or compliance issues.
    • If Durysta not used, document rationale for inability to use Durysta.
    Denial Risk

    Denial risk: missing required documentation

    Failure to provide required documentation (e.g., TTR mutation, baseline PND/FAP stage, confirmation testing for cardiomyopathy, prior topical/Durysta trials, or medical records demonstrating prior therapies and responses) may result in denial of the prior authorization.

    • Missing genetic or baseline severity documentation for transthyretin indications risks denial.
    • Missing prior topical/Durysta trial records for iDose TR risks denial.
    Denial Risk

    Denial risk: requests not meeting PA or Medicare criteria

    Requests that do not meet prior authorization criteria or that conflict with applicable Medicare NCDs/LCDs/LCAs or HAP coverage criteria may be denied.

    • Providers are responsible for checking applicable Medicare coverage guidance; Medicare guidance supersedes if conflict exists.
    Denial Risk

    Denial triggers: missing diagnostic or baseline data

    Lack of provided medical records supporting a request or missing required diagnostic documentation (e.g., TTR mutation, baseline PND ≤ IIIb or FAP Stage 1–2) may trigger denial.

    Denial Risk

    Coverage duration must align with standards of practice

    Coverage duration for some transthyretin cardiomyopathy indications must be within accepted standards of medical practice; deviations from standard coverage duration may result in non‑coverage.

    • Typical coverage duration referenced for many agents: up to 1 year.
    • Coverage duration must align with accepted standards of medical practice.
    Denial Risk

    Denial risk: inadequate prior therapy records

    Failure to provide supporting medical records of prior therapies and responses may result in denial; ensure records clearly show trials, dates, and outcomes.

    • Include documentation of prior therapies, dates, and clinical responses or intolerances.
    Denial Risk

    Denial risk: hemophilia prophylaxis documentation and exclusion

    For hemophilia prophylaxis, missing documentation that the patient has hemophilia A or B without inhibitors or evidence of required prior prophylaxis trials will risk denial; the policy also prohibits use in combination with other prophylaxis drugs.

    Denial Risk

    Denial risk: iDose TR missing step‑therapy documentation

    iDose TR requests that lack documentation of required prior topical prostaglandin trials and/or Durysta trial (or inability to use Durysta) may be denied.

    • Document which topical prostaglandin agents were tried and the clinical outcome.
    • If claiming inability to use Durysta, include the clinical rationale.
    Denial Risk

    Denial risk for missing supporting medical records

    Failure to provide supporting medical records with the request may lead to denial for any listed PA/ST drug.

    Denial Risk

    Denial risk: absent documentation of required topical trials

    Lack of supporting medical records or failure to document required prior topical prostaglandin trials will trigger denial for iDose TR requests.

    Denial Risk

    Denial risk: missing topical/Durysta trial evidence for implants

    Absence of required prior topical prostaglandin/Durysta trials or clinical documentation as specified may result in denial of requests for ophthalmic implant coverage.

    Denial Risk

    Denial risk: documentation absent or incomplete

    Lack of supporting medical records for a PA request may lead to denial; always attach relevant clinical notes, test results, and prior medication records.

    Denial Risk

    Basis for denial: unmet iDose TR clinical criteria

    Coverage of iDose TR requires documentation that the patient has open‑angle glaucoma or ocular hypertension and has met required prior trials; absence of these will form the basis for denial.

    Denial Risk

    Denial risk: prior topical therapy not demonstrated

    Requests lacking documentation that prior topical prostaglandin therapy was tried and failed (or Durysta when required) may be denied.

    Denial Risk

    Denial risk: missing diagnosis or failed prior trials

    Requests that do not document open‑angle glaucoma or ocular hypertension and failure of required prior topical prostaglandin trials (and Durysta where specified) may be denied.

    Denial Risk

    Denial risk: missing clinical criteria or medication trials

    Requests lacking documentation that the patient meets the clinical criteria for open‑angle glaucoma or ocular hypertension or has failed required topical prostaglandin trials (including Durysta when required) may be denied.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy Criteria

    Initial therapy / step requirements (examples)

    Examples of initial therapy/step requirements referenced in the drug list:

    Biosimilar and step examples: Step therapy often requires trial and failure of preferred biosimilars or alternative agents before coverage of non‑preferred products (examples: must first try Inflectra/Remsflexis/Hadlima before certain tocilizumab products; must first try Mvasi AND Zirabev before some bevacizumab products; must try Trazimera AND Kanjinti before other trastuzumab formulations).

    Examples are illustrative; follow drug‑specific nodes for exact requirements.

    Initial therapy

    Initial therapy prior authorization requirements

    Initial prior auth requirements: Provide medical records, documentation of TTR mutation (for hereditary TTR neuropathy), baseline PND ≤ IIIb and/or FAP Stage 1 or 2, and clinical signs/symptoms for hATTR FAP; for cardiomyopathy provide confirmation testing; age requirements apply where specified.

    Amvuttra/vutrisiran entries effective 1/1/2026.

    Initial therapy requirements

    Initial authorization requires:

    Initial: Submission of medical records; documentation of TTR mutation for hereditary neuropathy; baseline PND score ≤ IIIb and/or FAP Stage 1 or 2; documentation of clinical signs and symptoms.

    Required medical information group described in Amvuttra entries.

    Initial therapy (partial)

    Initial coverage notes: No additional detailed initial therapy dosing or duration specified in these chunks; confirmation of diagnosis and age ≥18 referenced for cardiomyopathy entries.N/A

    Partial document excerpt.

    Initial step requirements

    Initial coverage often requires prior trials of specified alternatives

    Herceptin-class initial requirement: Must first try the biosimilars Trazimera AND Kanjinti prior to coverage of other trastuzumab products.

    Applies to trastuzumab product entries.

    Bortezomib initial requirement: Must first try specified alternative bortezomib products (per J‑codes) before coverage of listed formulations.

    Step therapy examples for bortezomib/J‑codes.

    Hympavzi dosing

    Hympavzi initial dosing

    Hympavzi dosing: Loading dose: 300 mg (two 150 mg injections) subcutaneously; maintenance: initiate 150 mg weekly one week after loading; escalation to 300 mg weekly requires documented medical necessity.

    Initial authorization

    Initial authorization nodes: Medical records, diagnosis of open‑angle glaucoma or ocular hypertension, and prior therapy trials per the two‑pathway step therapy (Path A or B) are required for iDose TR.

    Failed defined as inadequate response, intolerance, or compliance issues.

    Initial therapy / authorization

    Initial approval requirements: Medical records; diagnosis of open‑angle glaucoma or ocular hypertension; meet step therapy options (Path A: one generic prostaglandin + Durysta; Path B: unable to use Durysta + two generic prostaglandin failures).

    'Failed' defined as inadequate response, intolerance, or compliance issues.

    Initial therapy requirements

    Initial coverage requires diagnosis, documentation, and specified prior topical therapy trials.

    Initial: Medical records provided AND diagnosis of open‑angle glaucoma or ocular hypertension AND either Path A or Path B must be met.

    Documentation of which agents tried and the nature of failure is required.

    Path A or B: Path A: tried and failed one generic prostaglandin topical drop (latanoprost, bimatoprost, travoprost) AND Durysta. Path B: unable to use Durysta AND tried and failed two generic topical prostaglandin drops.

    Failure = inadequate response, intolerance, or demonstrated compliance issues.

    Prior medication requirements

    Required prior medication trials: Either: (a) trial and failure of one generic prostaglandin eye drop (latanoprost, bimatoprost, travoprost) plus Durysta; OR (b) if patient cannot use Durysta, trial and failure of two generic topical prostaglandin eye drops.

    Failure defined as inadequate response, intolerance, or compliance issues.

    Initial therapy criteria

    Indication and trials: Patient has open‑angle glaucoma or ocular hypertension AND meets one of the prior trial pathways described in the coverage criteria.

    Age and prescriber restrictions: N/A unless specified elsewhere.

    Initial authorization

    Initial authorization: Patient has open‑angle glaucoma or ocular hypertension AND meets required topical prostaglandin/Durysta trial pathway as specified; documentation of failed trials required.

    One‑time administration per FDA labeling; coverage duration typically one course.

    Initial therapy

    Initial coverage requires:

    Initial drug requirements: Diagnosis of open‑angle glaucoma or ocular hypertension; required prior topical prostaglandin trials and Durysta conditions met; and medical records provided to document failures or intolerance.

    One‑time administration per FDA labeling; documentation must specify nature of failure (inadequate response, intolerance, or compliance issues).

    Initial therapy requirements

    Diagnosis: Open‑angle glaucoma or ocular hypertension.
    Prior topical therapy: (a) Tried and failed one generic prostaglandin drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) Unable to use Durysta and tried and failed two generic topical prostaglandin drops.

    'Failed' = inadequate response, intolerance, or demonstrated compliance issues.

    Initial coverage requirements

    Indication and trials: Diagnosis of open‑angle glaucoma or ocular hypertension AND required prior topical prostaglandin trials as specified (see criteria); documentation required for failed trials.

    Coverage is for a one‑time administration as indicated per FDA labeling or accepted standards.

    Reauthorization / Continuation Criteria

    Reauthorization clinical response requirements

    Reauthorization clinical response requirements

    Reauthorization examples: For certain agents reauthorization requires documentation of clinical improvement (examples: Entyvio — positive clinical response; Epysqli — decreased relapse rate for NMOSD; for myasthenia gravis improvement in MG‑ADL).

    Clinical outcome documentation required for reauthorization.

    Step Therapy Rules

    RequirementDetails
    Preferred/more cost-effective drug(s) must be tried and failed before advancing to a non-preferred Part B drug (step therapy).
    Applies to MAPD members who are not currently receiving the Part B drug; 'failed' is defined as inadequate response or intolerance documented by the provider or medical records.
    RequirementDetails
    Step therapy sequencing
    No specific step therapy steps or sequencing requirements are documented in the referenced chunks.
    RequirementDetails
    Step therapy requirement
    No step therapy requirement is specified in the provided chunks for this entry.
    ExampleStep therapy instruction
    Bevacizumab/ophthalmic agents
    Must try Avastin (bevacizumab) or specified biosimilars (examples: Mvasi and Zirabev) before certain ophthalmic agents as listed.
    RequirementDetails
    Trastuzumab biosimilar-first step
    Trial of the biosimilars Trazimera AND Kanjinti is required before coverage of other trastuzumab formulations (e.g., Herceptin and listed trastuzumab products).
    IndicationStep therapy requirement
    Hympavzi — Hemophilia A
    For hemophilia A prophylaxis: trial of two prophylactic agents is required and one must be Hemlibra; prescription must be written by a hematologist and medical records must document absence of inhibitors.
    Device/DrugPrior trial requirement
    iDose TR (travoprost intracameral implant)
    Requires prior topical prostaglandin therapy and Durysta per specified pathways: either one generic prostaglandin eye drop plus Durysta, or inability to use Durysta plus two failed generic topical prostaglandin drops; 'failed' defined as inadequate response, intolerance, or documented compliance issues.
    RequirementDetails
    Topical prostaglandin and/or Durysta trial
    Patient must meet one of two pathways: (a) tried and failed one generic prostaglandin topical drop (latanoprost, bimatoprost, travoprost) AND Durysta; OR (b) unable to use Durysta and tried and failed two generic topical prostaglandin drops. Failure = inadequate response, intolerance, or compliance issues.
    RequirementDetails
    Topical prostaglandin trial options
    Either: one generic prostaglandin drop plus Durysta; or if patient cannot use Durysta, failure of two generic topical prostaglandin drops (latanoprost, bimatoprost, travoprost). 'Failed' defined as inadequate response, intolerance, or compliance issues.
    RequirementNotes
    Prior authorization and prior trials required
    Trial(s) of generic topical prostaglandin(s) and/or Durysta per the two alternative pathways must be documented; prior authorization is required and medical records must support the failures or inability to use Durysta.
    RequirementDetails
    Topical prostaglandin and Durysta pathways
    Patient must have tried and failed either: (a) one generic prostaglandin eye drop (latanoprost, bimatoprost, travoprost) plus Durysta; OR (b) if unable to use Durysta, two generic topical prostaglandin drops. Failure = inadequate response, intolerance, or compliance issues.
    RequirementEvidence needed
    Documented failed trials per pathways
    Medical records must document the diagnosis (open-angle glaucoma or ocular hypertension) and the required prior medication trials per pathway A (one generic prostaglandin + Durysta) or pathway B (unable to use Durysta + two generic prostaglandins); 'failed' defined as inadequate response, intolerance, or compliance issues.
    RequirementDetails
    Prior topical prostaglandin drops and/or Durysta required
    Step therapy requires trial and failure of topical generic prostaglandin(s) and Durysta per the two alternative pathways described before iDose TR placement.
    RequirementDetails
    Pathway A or B for iDose TR
    Either: tried and failed one generic prostaglandin eye drop plus Durysta; OR unable to use Durysta and tried and failed two generic topical prostaglandin drops. 'Failed' = inadequate response, intolerance, or documented compliance issues.
    RequirementCoverage implication
    Prior trials required before coverage
    Member must have documented failure of the required topical prostaglandin and Durysta pathway (or two generic prostaglandin failures if Durysta cannot be used); documentation is required to support one-time administration approval.
    RequirementDetails
    Required topical prostaglandin trials (specific agents)
    Trial of generic prostaglandin eye drops (latanoprost, bimatoprost, or travoprost). If Durysta was tried and failed, one generic prostaglandin trial plus Durysta is sufficient; if Durysta cannot be used, two generic topical prostaglandin trials are required. 'Failed' defined as inadequate response, intolerance, or compliance issues.

    Quantity Limits and Administration

    iDose TR (travoprost) intracameral implant — One-time administration
    Quantity limitOne-time administration only
    DrugiDose TR (travoprost) intracameral implant
    Coverage noteCoverage limited to a single implantation as indicated per FDA labeling or accepted standards of practice
    iDose TR (travoprost) intracameral implant — one-time
    Administration limitOne-time
    ProductiDose TR (travoprost) intracameral implant
    DocumentationMedical records must support indication (open-angle glaucoma or ocular hypertension) and prior trial criteria for PA
    iDose TR (travoprost) intracameral implant — one-time
    Coverage frequencyOne-time administration
    IndicationOpen-angle glaucoma or ocular hypertension with required prior topical prostaglandin/Durysta trials
    PA requirementPrior authorization required and approval contingent on meeting prior trial pathways

    Site of Care

    Note
    Note
    Note

    Biosimilar and Alternative Preference

    Note
    Note
    Note
    Note
    Note

    Definitions

    Part B drug — Outpatient prescription drugs and biologicals eligible for coverage under Medicare Part B, usually administered by infusion or injection ...
    DefinitionOutpatient prescription drugs and biologicals eligible for coverage under Medicare Part B, usually administered by infusion or injection and not usually self-administered
    ContextPart B drugs are furnished incident to a physician or provider service
    Coverage guidanceHAP follows CMS NCDs/LCDs/LCAs when determining Part B coverage
    Medically Accepted Indication (MAI) — An indication defined by CMS that depends on the benefit (Part D vs Part B) and, for Part B, if no NCD/LCD/LCA exists HAP may cover unlab...
    DefinitionMedically Accepted Indication (MAI) is an indication defined by CMS that depends on the benefit (Part D vs Part B); for Part B, unlabeled uses may be covered if deemed medically accepted based on compendia and literature
    ApplicationWhen no NCD/LCD/LCA exists, HAP may review for MAI using compendia and accepted clinical literature
    Decision processHAP's P&T committee reviews coverage criteria when Medicare guidance is absent
    PND score / FAP stage — Baseline polyneuropathy disability (PND) score and Familial Amyloid Polyneuropathy (FAP) stages are measures used to describe severity of...
    DefinitionBaseline polyneuropathy disability (PND) score and Familial Amyloid Polyneuropathy (FAP) stages describe neuropathy severity; requirement: PND ≤ IIIb and/or FAP Stage 1 or 2 for hATTR FAP eligibility
    UseUsed to determine eligibility for Amvuttra (vutrisiran) coverage in hATTR FAP
    DocumentationMedical records must include baseline PND and/or FAP stage
    TTR mutation — Documentation of a pathogenic transthyretin (TTR) gene mutation (example given: V30M) required to support diagnosis of transthyretin-rela...
    RequirementDocumentation of a pathogenic transthyretin (TTR) gene mutation (example: V30M) is required to support diagnosis of hereditary transthyretin-related familial amyloid polyneuropathy
    ContextPart of required medical information for Amvuttra/vutrisiran PA requests
    EvidenceTTR mutation must be documented in submitted medical records
    PND score — Polyneuropathy disability score; policy requires baseline PND score less than or equal to IIIb for eligibility.
    DefinitionPolyneuropathy disability (PND) score; policy requires baseline PND score ≤ IIIb for eligibility
    ApplicationUsed to assess disease severity for hATTR FAP coverage decisions
    DocumentationBaseline PND score must be provided in medical records for PA
    FAP Stage — Familial amyloid polyneuropathy staging; policy references baseline FAP Stage 1 or 2 as acceptable.
    DefinitionFamilial amyloid polyneuropathy (FAP) staging; policy references baseline FAP Stage 1 or 2 as acceptable for coverage
    UsePart of baseline severity criteria for hATTR FAP authorization
    DocumentationBaseline FAP stage must be documented in submitted medical records
    TTR mutation — Pathogenic transthyretin gene mutation (example given: V30M) required to document hereditary transthyretin-related familial amyloid polyn...
    RequirementPathogenic transthyretin (TTR) gene mutation (e.g., V30M) required to document hereditary transthyretin-related familial amyloid polyneuropathy
    ContextPart of Amvuttra (vutrisiran) initial coverage documentation
    Evidence submissionGenetic test result should be included in PA medical records
    Transthyretin amyloid cardiomyopathy — Mentioned as an indication (wild-type or hereditary) for which diagnosis confirmation is required; no further definition provided in thes...
    DefinitionTransthyretin amyloid cardiomyopathy (wild-type or hereditary) — diagnosis confirmation with appropriate testing is required
    Age requirementPatient must be at least 18 years of age for cardiomyopathy indication
    DocumentationProvide confirmation testing results with PA submission
    Reauthorization requirements — For reauthorization some drugs require documentation of clinical improvement (e.g., reduction in relapse rate for NMOSD, improvement in M...
    Reauthorization evidenceFor some agents, reauthorization requires documentation of clinical improvement (examples: decreased relapse rate for NMOSD, improved MG-ADL for myasthenia gravis)
    PurposeUsed to justify continued coverage at reauthorization
    ExamplesEpysqli: decreased relapse rate; Myasthenia gravis treatments: improvement in MG-ADL
    Failed — Defined as a trial with an inadequate response or intolerance, or a trial with demonstrated compliance issues with glaucoma eye drops.
    Failed definitionFailed trial defined as inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops
    ApplicationUsed in step-therapy criteria for iDose TR and other ophthalmic implants
    DocumentationProvider must document trial outcome (response/intolerance/compliance) in medical records
    PND score / FAP stage — Baseline polyneuropathy disability (PND) score and Familial Amyloid Polyneuropathy (FAP) stages are measures used to describe severity of...
    Step/coverage requirementPatient must have tried and failed one generic prostaglandin eye drop plus Durysta OR be unable to use Durysta and have failed two generic topical prostaglandin drops
    IndicationRequired prior therapy pathways for iDose TR (travoprost) intracameral implant
    Failure definition'Failed' = inadequate response, intolerance, or demonstrated compliance issues; must be documented
    PND score — Polyneuropathy disability score; policy requires baseline PND score less than or equal to IIIb for eligibility.
    Most actionable requirementBaseline PND score ≤ IIIb OR baseline FAP Stage 1 or 2 must be documented for hATTR FAP PA
    Supporting itemsAlso require TTR mutation documentation and clinical signs/symptoms in medical records
    EffectivityAmvuttra (vutrisiran) entries effective 1/1/2026 per policy
    FAP Stage — Familial amyloid polyneuropathy staging; policy references baseline FAP Stage 1 or 2 as acceptable.
    Acceptable baseline stagesBaseline FAP Stage 1 or 2 acceptable for hATTR FAP coverage
    Associated requirementsMust be accompanied by TTR mutation documentation and clinical signs/symptoms
    DocumentationInclude staging in submitted medical records for PA
    TTR mutation — Pathogenic transthyretin gene mutation (example given: V30M) required to document hereditary transthyretin-related familial amyloid polyn...
    Required genetic evidencePathogenic TTR mutation (example V30M) must be documented to support hereditary TTR-FAP diagnosis
    ContextPart of Amvuttra/vutrisiran initial coverage documentation
    Provider actionAttach genetic test results to PA submission
    Transthyretin amyloid cardiomyopathy — Mentioned as an indication (wild-type or hereditary) for which diagnosis confirmation is required; no further definition provided in thes...
    DefinitionTransthyretin amyloid cardiomyopathy — requires confirmation of diagnosis with appropriate testing
    Age minimumPatient must be ≥18 years for cardiomyopathy indication
    DocumentationProvide confirmation testing results as part of PA medical records
    Reauthorization requirements — For reauthorization some drugs require documentation of clinical improvement (e.g., reduction in relapse rate for NMOSD, improvement in M...
    Reauthorization evidence requiredDocumentation of clinical improvement (e.g., decreased relapse rate for NMOSD) required for reauthorization of some agents
    ExampleEpysqli: decreased relapse rate for NMOSD; Myasthenia gravis: improvement in MG-ADL for reauth
    Provider actionSubmit outcome data with reauthorization requests
    Failed — Defined as a trial with an inadequate response or intolerance, or a trial with demonstrated compliance issues with glaucoma eye drops.
    Failed trial definitionFailed = inadequate response, intolerance, or demonstrated compliance issues with glaucoma eye drops
    UsageApplies to step therapy for iDose TR and determination of prior topical therapy failure
    DocumentationProvider must document reason for failure in medical records for PA
    Failed — A trial with an inadequate response or intolerance, or a trial with demonstrated compliance issues with glaucoma eye drops.
    Most actionable stepiDose TR requires prior trial and failure of topical prostaglandin(s) ± Durysta per two-pathway criteria before approval
    Pathway detailsEither one generic prostaglandin + Durysta OR inability to use Durysta and two generic prostaglandin failures
    DocumentationMedical records must document agents tried and reasons for failure/intolerance/compliance issues